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Background. Multiple chemical sensitivity (MCS) is a chronic condition characterized by an exaggerated response to toxicants. We
ascertained the prevalence of allergy to metals and toxicological aspects in MCS patients.Methods. We conducted a retrospective
review of medical records of 41 patients with MCS. We performed patch testing (𝑛 = 21) for dental series and did lymphocyte
transformation test (𝑛 = 18) for metals. We measured mercury in samples of blood (𝑛 = 19), urine (𝑛 = 19), saliva (𝑛 = 20),
and scalp hair (𝑛 = 17) to investigate the association between mercury levels and cases of MCS. Results. The prevalence of metal
immune hypersensitivity in a subset of 26 patients was 92.3 percent. Elevations of mercury occurred in 81.2 percent (26 of 32).
The mean (±SD) in blood concentrations of mercury was 7.6 ± 13.6 𝜇g/L; mean in urine was 1.9 ± 2.5 𝜇g/L; mean in scalp hair
was 2.2 ± 2.5 𝜇g/g; mean in saliva was 38.1 ± 52.1 𝜇g/L. Subgroup analyses showed that elevation of mercury levels in biological
matrices were associated with mercury amalgams in patients with MCS (22 patients), compared with controls (8 patients) (odds
ratio 11 : 95 percent confidence interval 1.5 to 81.6; 𝑃 = 0.023). Conclusions. Our data show an increased prevalence of metal allergy
and elevation of mercury levels in bioindicators among patients with MCS.
1. Introduction
Multiple chemical sensitivity (MCS)—also termed idiopathic
environmental intolerance (IEI)—is a chronic condition
characterized by an exaggerated body response to chemical
toxicants, especially organic solvents [1–6]. The symptoms
experienced and reported by patients are usually of the respi-
ratory, musculoskeletal [7], and gastrointestinal tracts [8–12].
Symptoms of hyperosmia [13] of the brain are commonly
described in patients with MCS when exposed to chemical
substances [14, 15]. Thus, it has long been thought that MCS
has a strong environmental component [16–20]. The preva-
lence of MCS is reported to range from 10 to 15 percent in
the general population [21, 22] and its pathogenesis remains
elusive. Numerous mechanisms have been implicated in the
etiologic process of MCS, including N-methyl-D-aspartate
(NMDA) sensitization [23, 24], peroxynitrite and nitric oxide
elevation [24, 25], oxidative stress [26, 27], proinflamma-
tory cytokines [26, 27], altered redox enzymes [26, 27],
cytochrome P450 metabolism [26–28], hypoxia [29], sero-
tonin receptors [30], neural sensitization [17, 31–35], and neu-
rogenic inflammation [36]. As a consequence, various studies
have suggested that persistent symptoms of MCS impaired
health-related quality of life in these patients [37, 38]. And
there is evidence thatmercury exposuremay cause symptoms
that clinically overlap with MCS. To test this hypothesis,
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we conducted a retrospective cohort study to determine
(i) whether patients with MCS had detectable levels of
mercury due to chronic environmental metal exposure and
(ii) whether patients withMCS had allergy tometals since we
hypothesized a priori that these exposuresmight play a causal
role in MCS. Our aim, therefore, was to measure the levels
of mercury in human biological matrices. We also sought to
determine the outcomeof allergic reactions tometals by using
in vivo patch testing and/or in vitro lymphocyte transforma-
tion test (LTT).
2. Materials and Methods
2.1. Study Oversight. We evaluated 41 consecutive patients
who had been referred for MCS (39 women and 2 men);
mean [±SD] age of the patients at their first study visit was
44.8±11.2 years. To studymetal immune hypersensitivity, we
did in vivo patch testing for dental series in 21 subjects, andwe
also did in vitro lymphocyte transformation test (LTT) for 20
metal allergens in 18 case subjects. We analyzed for concen-
trations of total mercury (elemental, inorganic, and organic
mercury) in samples of peripheral whole blood, urine, saliva,
and scalp hair and we tested for an association between alter-
ations in the levels of mercury and MCS by means of induc-
tively coupled plasma mass spectrometry method and/or
atomic absorption spectrometry. The total number of silver-
mercury amalgam restorations was charted, and we recorded
when amalgam restorations were placed in teeth in order to
correlate approximately the median duration of dental amal-
gam exposure (Table 1). None of the patients had been occu-
pationally exposed to mercury.
2.2. Definition and Clinical Diagnostic Criteria of MCS. MCS
is characterized by adverse health effects related to—or
exacerbated by—exposure to chemical substances. The most
common chemicals triggers of MCS are organic solvents,
metals, volatile organic compounds (VOCs), chlorine, drugs,
perfumes, hairsprays, diesel exhaust fumes, and pesticides.
MCS was defined by the presence of following MeSH code:
D018777. Even though an accurate classification remains
difficult, criteria for entry in our cohort were similar to those
described by Cullen [1, 2, 39]. Of the 53 patients evaluated for
the study, 41 were eligible and we excluded 12 patients (12 of
53, 41) who had reported a probable MCS but they did not
meet the above classification criteria [1, 2, 39].
2.3. Immunological Assay and Immune Markers. Allergic
sensitization to metals contained inmercury dental amalgam
restorations was ascertained on the basis of patch testing
done on the upper back. Most of the patients (𝑛 = 21) were
patch testedwith the Italian dental screening series (SIDAPA)
obtained from Chemotechnique Diagnostics AB (Malmo¨e,
Sweden). Readings were taken on day 2 (48 hours) and day 4
(96 hours). With regard to the pathophysiology of allergic
reactions induced bymetal allergens, they aremost frequently
mediated by type IV immune reactions (delayed-type hyper-
sensitivity reaction), according to the Gell and Coombs clas-
sification. Patch testing was integrated with the lymphocyte
Table 1: Distribution of patients as stratified according to study
cohort and the total number [mean (±SD)] of mercury-containing
dental amalgam fillings.
Sex - no. (%)
Female 39 95.1%
Male 2 4.9%
Patients with dental amalgam fillings 27 65.9%
Mean age 42.4 ± 10.5
No. mercury amalgam fillings
Mean 3.8 ± 2.7
Patients without dental amalgam fillings 14 34.1%
Mean age 49.3 ± 11.7
transformation test (LTT), a noninvasive test in vitro to deter-
mine cell-mediated immunological responses to metals and
metalloids [40]. In most of the patients (𝑛 = 18), we used a
highly sensitive and optimized LTT method in human lym-
phocytes (LTT-MELISAⓇ - Memory Lymphocyte Immune
Stimulation Assay) [41]. Data were expressed as a stimulation
index (SI), which was calculated from the quotient of test
counts per minute (cpm) and the average cpm from
three negative controls [40, 41]. No corticosteroids and/or
immunosuppressive drugs were taken for at least twomonths
before skin contact patch-test allergens and/or the LTT.
No subjects had used nonsteroidal antiinflammatory drugs
(NSAIDs), antibiotics, and H
1
-anti-histamine agents within
the previous three weeks before patch testing and/or the LTT.
None of these medications were permitted for all routes of
administration (enteral, parenteral, topical, and/or by inhala-
tion), whichmay alter the immunological response tometals.
2.4. Sampling and Mercury Analysis of Biological Specimens.
We have measured total mercury concentrations in whole
blood samples and urine samples in 19 of 41 patients (46.3%)
with MCS (Table 3). At the time of admission, fasting morn-
ing venous peripheral whole blood samples (4 milliliters)
were collected in mercury-free polypropylene tubes con-
taining potassium EDTA (K2-EDTA), as an anticoagu-
lant. First morning urine specimens (100 milliliters) and/or
24-hour urine collection specimens were obtained and stored
at +4∘C until mercury analysis. All blood and urine samples
were delivered immediately to the laboratory of toxicology
for mercury analysis and were processed within 24–72 hours
after collection. Concentrations of total mercury in whole
blood, urine, and chewing gum-stimulated whole saliva
samples in our cohort were measured by cold vapor atomic
absorption spectrometry (CVAAS) [42, 43] and/or ICP-MS
(inductively coupled mass spectrometry) methods [43]. The
lower limit of detection (LD) for total mercury in both blood
and urine was 0.05 micrograms per liter. The intraassay and
interassay coefficients of variation, determined at various
concentrations, were 2 percent and 5 percent, respectively.
External and internal quality-control procedures were made.
We also determined totalmercury in head hair in a small sub-
group of 17 subjects (17 of 41, 41.4 percent), and human scalp
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hair samples were taken from the occipital region of the head
with sterile stainless steel surgical scissors. Each specimen of
head hair was collected from the first three centimeters (3
centimeters hair segments) in length next to the scalp, and
it was weighed. The overall mean [±SD] weight of the hair
specimens was approximately 220±110milligrams. Mercury
hair analysis is proper indicator medium for determining
organic mercury, and it reflects exposure that occurred dur-
ing the last fewmonths. Total mercury in strands of scalp hair
was measured with ICP-MS system.The detection limit (DL)
of mercury in scalp hair was 0.07 micrograms per gram [44].
To avoid loss of mercury in head hair, none of the 17 patients
received hair dyes three months before the hair sampling
procedure. Toenails samples were collected from only one
subject to confirm the level of exposure to mercury (data not
shown). To examinewhether there were significant elevations
in totalmercury levels in saliva, we collected stimulated saliva
specimens after chewing a sugar-free gum for 5–10 minutes
before collection, and subsequently mercury content was
quantified by atomic absorption spectrometry (AAS) [45].
The operational lower limit of detection (LD) for mercury in
saliva was 0.1 micrograms per liter [46]. To assess average fish
or seafood consumption, we used a semiquantitative food-
frequency questionnaire, which included distinct questions
about other dietary variables (i.e., alcohol and—as contribu-
tion to the total caffeine intake—coffee, tea, and chocolate).
We also estimated modifiable risk factors (i.e., smoking) for
MCS among patients, using data derived from interviews,
questionnaire [47], and themedical records. All subjects gave
oral and written informed consent. This retrospective obser-
vational case series study was conducted from 2001 to Febru-
ary 5, 2013, which was the cutoff date for analyses of all cases
of MCS. The corresponding author gathered the data and
vouch for its accuracy.
2.5. Interventions. Our team developed a new method to
remove mercury amalgam fillings by using the en bloc
technique [48]. Treatment method includes complete dental
amalgam removal. It is good clinical practice to avoid unnec-
essary overexposure to mercury vapor during the removal
of dental amalgam [48]. The dentist was well trained and
performed at least 80 mercury amalgam removal annually.
2.6. Statistical Analysis. All statistical tests, performed with
the use of SPSS software, version 19, were two sided, and a 𝑃
value of less than 0.05 was considered to indicate statistical
significance. The statistical tests used were chosen after con-
firmation of the distribution of normality of the sample with
the Kolmogorov Smirnov test. Comparison of continuous
variables between the two groups was conducted with the use
of the Mann-Whitney𝑈 test for variables with a non-normal
distribution. Chi-square tests were used for the comparison
of categorical variables and the Fisher’s exact test was used
where appropriate. The association between two casual vari-
ables has been detected with the Correlation Pearson (𝑟) test.
All data are expressed as means ±SD.
Table 2: Distribution of 41 cases of multiple chemical sensitivity in
the Italy cohort.TheMCS cohort contained 39 (95.1 percent) women
and 2 (4.9 percent) men.
Regions of Italy Patients no. % of total
Lombardy 23 56.10
Emilia-Romagna 4 9.75
Lazio 5 12.19
Trentino-Alto Adige/Su¨dtirol 3 7.32
Veneto 3 7.32
Apulia 1 2.44
Campania 1 2.44
Calabria 1 2.44
3. Results
3.1. Patients. The total of 41 patients with MCS were of white
race. Patients were of Caucasian adult origin and were identi-
fied as Italy-born persons. Most patients were fromNorthern
Italy (80.5 percent), Central Italy (12.2 percent), and Southern
Italy (7.3 percent) (Table 2). The mean age of patients with
MCS was 44.8 ± 11.2 years; 95.1 percent (39 patients) were
female and 2 were men (Table 3). Female mean age was 45 ±
11.3 years and men mean age was 36 years. Details of marital
status are shown in Figure 1. The acquisition of MCS was
largely associated with female sex; female to male ratio was
19.5 : 1.
3.2. Prevalence of Allergy to Metals among Patients with MCS.
In the cohort of patients screened with both patch testing and
the lymphocyte transformation test (LTT), the cumulative
prevalence of allergic sensitization tometals in 26 patients (26
of 41, 63.4 percent) was 92.3 percent. In order to compare the
frequency of allergy to metals using the two methods, patch
testing for dental series was assessed in 21 of our series of 41
patients (51.2 percent). Positive allergic patch test reactions
to metal allergens were noted in 17 of 21 participants (80.9
percent).The prevalence of positive reactions tometals by the
lymphocyte transformation test (LTT) was 94.4 percent (17 of
18). 5 patients (5 of 18, 27.7 percent) refused patch testing for
contact allergy procedures to establish possible sensitization
to dental materials because of contact with metal allergens
and the subsequent risk of flare-up of MCS symptoms, there-
fore, they choose to use another laboratory test: an in vitro
testing, the lymphocyte transformation test (LTT). In 13
patients (13 of 18, 72.2 percent) sensitization to metals
was reported with the use of both methods—skin patch
testing and the LTT. When assessed according to mercury-
compound allergens by patch testing with a dental screening
series (in aggregate; metallic mercury, ammoniated mercury,
thimerosal, phenyl mercury, and mercury dental amalgam,
all of which in petrolatum) and/or the lymphocyte transfor-
mation test (LTT), allergy to mercury was diagnosed in 13
patients of 26 (50 percent). We also found that 22 patients of
26 (84.61 percent) had allergy to other metallic components
of dental amalgam, which is the metal-matrix alloy of
dental amalgam. By excluding mercury compound allergens,
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Table 3: Mean [±SD] total mercury concentrations in biological matrices (whole blood, urine, saliva, and scalp hair).
Characteristics Total cohort with MCS patients
Concentrations of total
mercury in biological matrices
micrograms/liter
Reference range
micrograms/liter
41
Sex - no. (%)
Female 39 95.1%
Male 2 4.9%
Age at diagnosis of MCS
Mean 44.8 ± 11.2
Range (min–max) 25–65
Total cases of Hg in blood 19
Mean 7.6 ± 13.6 ≤2.0
Total cases of Hg in urine 19
Mean 1.9 ± 2.5 ≤2.0
Total cases of Hg in saliva§ 20
Mean 38.1 ± 52.1 ≤2.7
Total cases of Hg hair analysis 17
Mean 2.2 ± 2.5 ≤2.0∗
§Total mercury was measured in gum-stimulated saliva samples.
∗Total mercury in scalp hair was expressed in micrograms per gram.
Married
44%
Singles
29%
Marital status:
missing
27%
Figure 1: Marital status of the cohort of MCS patients.
the most common metal immune hypersensitivity reactions
associated with amalgam metal-matrix alloy were—listed in
decreasing order of frequency—nickel, cadmium, palladium,
gold, chromium, and silver.
3.3.Mercury Analyses. Of 19 patients who could be evaluated,
in 19 of 41 (46.3 percent) the mean mercury whole blood
levels was 7.6 ± 13.6 micrograms per liter (range from 0.5
to 59.4 micrograms per liter); normal range from 0 to 2. Of
19 patients considered, in 19 of 41 (46.3 percent), the mean of
urinemercury levels was 1.9±2.5micrograms per liter (range
from 1 to 10 micrograms per liter); normal range from 0 to 2.
Of 17 patients evaluated, in 17 of 41 (41.5 percent), themean of
total mercury accumulated in scalp hair was 2.2 ± 2.5micro-
grams per gram (range from 0.06 to 8.45 micrograms per
gram); normal range from 0 to 2. Of 20 patients evaluated,
20 of 41 (48.8 percent), the mean of salivary mercury levels in
chewing gum-stimulated whole saliva was 38.1 ± 52.1micro-
grams per liter (range from 0.1 to 168 micrograms per liter);
upper limit value <2.7 (Table 3). In a subgroup analysis of 24
patients, 22 patients with mercury dental amalgam fillings
(91.7 percent), levels of total mercury in human biological
matrices (in aggregate; whole blood, urine, scalp hair, and
saliva) correlate with the total number of mercury dental
amalgam tooth fillings, as compared with 4 patients (50
percent) without mercury dental amalgams (odds ratio, 11; 95
percent confidence interval, from 1.5 to 81.6; 𝑃 = 0.023)
(Table 4). In a subgroup of 27 (27 of 41, 65.8 percent)
patients with MCS who carry dental amalgam fillings, we
also observed a strong correlation between the number of
mercury-containing dental amalgam fillings and the concen-
trations of total mercury in urine (𝑟 = 0.71, 𝑃 = 0.002). No
other variables were associated with a statistically significant
increase in level of total mercury in biological matrices
(including fish consumption).
3.4. Mercury Amalgam Tattoos and MCS. The prevalence of
amalgam tattoo of human oral mucosa at the time of first visit
was 17 percent (7 of 41), which wasmore than twice as high as
the prevalence among a sample in the Swedish population in
whom the prevalence of amalgam tattoo is remarkably high
[49]. Intraoral mercury amalgam tattoos are known to have
the highest levels of total mercury (inorganic mercury along
with organic mercury) compared to any other tissues and
organs in humans [50]. Previous estimates of the prevalence
of amalgam tattoo ranging from 0.4 to 8.2 percent in the
general population [49]. Amalgam tattoo should be surgically
removed in case of allergy to mercury.
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Table 4: Increased levels of mercury in biological matrices in patients with MCS who have mercury dental amalgams.
Patients with mercury
amalgam fillings
Patients without mercury
amalgam fillings Total patients 𝑃 value Odds ratio
Number 24 8 32 0.023 11
Yes 22 (91.7%) 4 (50.0%) 26 (81.3%)
No 2 (8.3%) 4 (50.0%) 6 (18.7%)
In a subgroup analysis of 24 patients, 22 patients with dental amalgam (91.7 percent), levels of total mercury in biological matrices (in aggregate; whole blood,
urine, scalp hair, and saliva) correlate with the number of mercury dental amalgam tooth fillings, as compared with 4 patients (50 percent) without dental
amalgams (odds ratio, 11; 95 percent confidence interval: from 1.5 to 81.6; 𝑃 = 0.023).
Table 5: Adverse health effects occurring in 33.3 percent of patients (11 of 33) who underwent mercury dental amalgam removal without
adopting safety measures.
Patient
no. Sex
Age at
diagnosis
No. of total
mercury
amalgam fillings
Reported adverse events Allergy tometals∗
Blood
mercury
levels 𝜇g/L
Urine
mercury
levels 𝜇g/L
Scalp hair
mercury
levels 𝜇g/g
Saliva
mercury
levels 𝜇g/L
1 F 52 PR‡ Fever of unknown origin Thimerosal 0.5 0.5 0.06 NA∗∗
2 F 31 2 Asthma attacks Nickel 2.7 0.7 NA 0.7
3 F 27 2 Asthma attacks Thimerosalnickel 59.4 4 8.2 1.3
4 M 36 PR Tunnel vision, trigeminalneuralgia, metallic taste
Inorganic
mercury NA NA 0.2 0.2
5 F 39 PR Hyperosmia, asthma attacks NA NA NA NA NA
6 F 29 5 Fever of unknown origin NA 1.1 0.3 NA 2.4
7 F 61 2 Atypical facial pain NA NA NA 2.8 2
8 F 31 PR Fatigue, muscle pain Nickel NA NA NA NA
9 F 58 1 Facial paresthesia, metallic taste,ocular inflammation NA 7.6 0.5 4.03 0.7
10 F 47 2 Vertigo, asthma attacks, prickingpain in arms NA 2.7 0.5 1.3 NA
11 M 36 2 Fatigue, muscle pain/weakness Inorganicmercury 3.5 0.5 NA 9.2
∗Allergy to mercury: patients were tested with skin patch testing and/or lymphocyte transformation test (LTT).
‡PR: previously removed, number of mercury amalgam undefined.
∗∗NA: not analyzed.
3.5. Mercury Dental Amalgam as a Risk Factor. 41 patients
with MCS were evaluated for appropriate treatment of
adverse events to dental materials, particularly to exposure to
dental metal alloys (i.e., mercury-containing dental amalgam
fillings). 27 of 41 patients (65.9 percent) had mercury dental
amalgam fillings and 14 of 41 (34.1 percent) did not have
mercury amalgam tooth fillings.The average number of mer-
cury amalgam restorations of persons in the cohort who carry
dental amalgamwas 3.8±2.7, ranging from 1 to 10. In 18 of 27
(66.6 percent) patients with mercury amalgam, the mean
duration of exposure to mercury amalgam tooth fillings was
25.1 ± 9.5 years before the onset of definite clinical mani-
festations of micromercurialism after long-term exposure to
mercury dental amalgam.
3.6. Adverse Events after Mercury Amalgam Removal. A total
of 11 patients (11 of 33, 33.3 percent) of the cohort reported
having had at least one major adverse outcome related to
dental amalgam removal without safe procedures (Table 5).
All 11 patients underwent dental amalgam removal at the
various dental centers. Clinical manifestations and adverse
outcomes that were considered to be related to toxic effects
of acute overexposure to mercury vapors during amalgam-
removal treatment were as follows: dysgeusia (metallic taste),
constriction of the visual fields (tunnel vision), trigemi-
nal neuralgia, atypical facial pain, burning mouth disorder
(BMS), cervical lymphadenopathy, axillary lymph nodes
enlargement, bronchial hyperresponsiveness and asthma
attacks, skin rashes (salmon-colored and/or pink’rash),
headache, lightheadedness, weight loss, vertigo, muscle
pain/weakness, fatigue, fever of unknown origin (FUO-body
temperature ≥37.5∘C). The adverse events reported in each
patient are listed in Tables 5 and 6. In the Table 6, these
adverse events were associated with long-term exposure to
mercury amalgam and/or due to high levels of mercury
vaporization emitted during amalgam removal by standard
drill-out method, which is no longer recommended [48].
3.7. Treatment and Mercury Amalgam Replacement. Elemen-
tal and inorganic mercury’s biological half-life is rather
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Table 6: New and classical systemic signs and symptoms associated
with mercury exposure among MCS patients cohort.
Signs
(i) Angioedema N
(ii) Cervical and axillary lymph nodes swollen N
(iii) Dermographism C
(iv) Enlargement of thyroid C
(v) Eyelid myokymia (eyelid tremors) N
(vi) Gastrointestinal malabsorption N
(vii) Gingivitis - Stomatitis C
(viii) Lichenoid contact stomatitis N
(ix) Low-grade fever (fever of unknown origin—FUO) N
(x) Muscle atrophy N
(xi) Muscle fasciculations C
(xii) Non-allergic rhinitis/vasomotor rhinitis-like N
(xiii) Peripheral neuropathy C
(xiv) Salmon-colored and/or pink’ rash C
(xv) Sialorrhea (hypersalivation) C
(xvi) Spasms C
(xvii) Systemic contact dermatitis N
(xviii) Tremors (upper limb, hands, fingers, face, eyelids,
and lips) C
(xix) Urticaria N
(xx) White matter hyperintensity (by brain MRI) N
(xxi) Xerostomia (dry mouth) C
Symptoms
(i) Abdominal cramps N
(ii) Anorexia C
(iii) Atypical facial pain (persistent idiopathic facial pain) N
(iv) Burning mouth syndrome (BMS) N
(v) Burning pain (neuropathic) C
(vi) Chemical odor intolerance N
(vii) Chest pain (anterior or posterior, on the left side) N
(viii) Confusion C
(ix) Depression C
(x) Dysesthesia N
(xi) Fatigue C
(xii) Flu-like symptoms N
(xiii) Headache C
(xiv) Insomnia N
(xv) Intestinal movement disorders N
(xvi) Intolerance to odors N
(xvii) Itching (neuropathic) N
(xviii) Muscle weakness C
(xix) Nausea C
(xx) Noise sensitivity N
(xxi) Paresthesia C
(xxii) Photophobia N
(xxiii) Recurrent infections N
(xxiv) Short-term memory disturbances C
(xxv) Tachycardia C
(xxvi) Thermal regulation disorders (low cold tolerance) N
(xxvii) Trigeminal neuralgia N
(xxviii) Vertigo C
The table lists signs and symptoms triggered by mercury amalgam exposure
and also noting those defined as “new” and “classical” signs and symptoms
related to exposure to mercury amalgam in a cohort of patients with MCS.
(N) and (C) denote “new” and “classical” signs and symptoms.
protracted and ranged from 30 to 90 days, averaging 60 days
[51]. Most patients who develop MCS following exposure
Table 7: Recommended threshold levels in matrices for biological
monitoring of total mercury in humans after complete mercury
dental amalgam removal. Very low level of mercury in bioindicators
are able to reverse clinical manifestations as well as abnormal
laboratory values associated with mercury amalgam exposure.
Mercury levels Threshold limitvalues
Unit of
measurements
Total Hg in scalp hair ≤0.5 micrograms/g
Total Hg in whole blood <1.5 micrograms/L
Total Hg in serum <1.5 micrograms/L
Total Hg in plasma <1.5 micrograms/L
Total Hg in urine ≤1.0 micrograms/L
Total Hg in saliva ≤0.5 micrograms/L
Total Hg in breast milk ≤0.5 micrograms/L
Total Hg in nails ≤0.5 micrograms/g
Total Hg in intraoral cavity ≤1.5 micrograms/m3
to mercury amalgams show improvement within one year
(mean time to resolution = 6 months), after the removal of
the remainingmercury dental amalgams. Usually, best results
appear to be achieved one year after the last dental amalgam
replacement.
3.8. Outcomes. 16 of 41 (39 percent) patients with MCS were
treated by our dental team, in accordance with the en bloc
technique, in which we do not touch the mercury amalgam
filling with tungsten burr [48]. The level of whole blood total
mercury, the level of urinary total mercury, and the concen-
trations of totalmercury in saliva all decreased significantly—
fell below measurable levels—following mercury amalgam-
replacement within 6 to 12months in 6 patients. After amean
follow up of 41.3 months (ranged from 13 to 130 months),
at the end of total mercury amalgam removal, 10 of 16 (62.5
percent) patients reported that their symptoms had improved
markedly (>50 percent), according to the patient’s subjective
assessment. In 37.5 percent (6 of 16) the condition of these
patients improved onlymoderately (<50 percent) after receiv-
ing dental amalgam replacement (Table 7). The patients with
allergy to metals had the better prognosis and control of
symptoms. No side effects were reported with a safe and
effective dental amalgam removal.
3.9. Body-Mass Index and MCS. The body-mass index—the
weight (kg) divided by the square of the height (m)—did not
differ significantly in MCS patients. The overall average body
mass index (BMI) of 38 female patients and 2 male patients
with MCS was 21.3 ± 3.28 (range min–max: 17–30).
3.10. Hormonal Risk Factors andMCS. A subgroup of 13 sub-
jects (13 of 41, 31.7 percent) showed hormone disorders, and—
of the patients who could be evaluated—an elevated serum
prolactin level was detected in 4 of 13 patients (30.8 percent),
which means that the endocrine system was found to be
deregulated.This corroborates other research suggesting that
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there was a positive association between the increase in circu-
lating serum prolactin levels and exposure to mercury. 2 of 4
of these patients had allergy to mercury (metallic mercury
and mercury dental amalgam, resp.), and they had elevated
levels of mercury in saliva samples (17.6 and 49.6 micrograms
per liter, resp.). 5 of 13 patients (38.5 percent) had hypothy-
roidism. 3 of 13 patients (23.1 percent) had hyperthyroidism.
Adrenal gland disorders were seen only in one female patient.
3.11. MCS, Fibromyalgia, Chronic Fatigue Syndrome, and EHS.
Chronic fatigue syndrome (CFS) as well as fibromyalgia were
the most common coexisting conditions (fibromyalgia: 11 of
41, 26.8 percent; CFS: 11 of 41, 26.8 percent, resp.). Of 27
patients evaluated, in 14 of 27 (51.9 percent), electromagnetic
hypersensitivity symptoms (EHS) were self-reported.
3.12. Demyelinating Disorders and MCS. Two patients (2 of
41, 4.9 percent) received a diagnosis of demyelinating disor-
ders within a few months either before or after the diagnosis
of MCS.
3.13. Dietary Variables and MCS. In 27 patients of 41 (66
percent) the mean consumption level of fish and/or seafood
was 1.7 (8.5 oz) fish serving meal per week. It has been
reported that foods and beverages (alcoholic) may alter the
level of exposure to elemental mercury (Hg0) emitted from
amalgams in humans. Of 32 patients evaluated, in 11 of 32
(34.4 percent) the level of alcohol consumption per week was
2.43 ± 1.9. Of 32 patients evaluated, 20 of 32 (62.5 percent),
the average of coffee consumption per week was 14.7 ± 7.7.
Of 32 patients evaluated, 10 of 32 (31.2 percent), the mean
number of tea intake weekly was 3.1 ± 2.5. Of 27 patients
evaluated, 11 of 27 (40.7 percent) patients reported that con-
sumption perweek of chocolate was 1.1±1.The role of dietary
factors (i.e., alcohol, coffee, and tea) in the development of
MCS remains to be elucidated.
3.14. Smoking Status. Of the 35 subjects who were evaluated
for smoking, 4 of 35 (11.4 percent) were current tobacco
smokers, 9 were former smokers (25.7 percent), and 22 were
nonsmokers (62.9 percent).
3.15. Other Laboratory Features. It has been suggested that
mercury is able to induce a hematologic immunotoxicity. To
address this, we estimated total white blood cells (WBCs)
count as a subclinical index of mercury immunotoxicity. Of
19 patients who could be evaluated, 6 of 19 (31.6 percent),
the average of white blood cells (WBCs) was 5.9 ± 1.5 108
per liter. There was no evidence of the reduction in leukocyte
count.We also tested plasma homocysteine concentrations as
a subclinical index of mercury vasculotoxicity. Of 15 patients
evaluated, 7 of 15 patients (46.7 percent), the average of serum
level of homocysteine was borderline low at 13.8 ± 2.7 𝜇mol
per liter; normal level, <14. The immunoglobulin E (IgE)
level was mildly increased in 16 patients assessed, 6 of 16
(37.5 percent), the average of IgE was 350.1 ± 181.9UI per
milliliter (normal range 0–100UI permilliliter).These results
46%
Rural areas
54%
Metropolitan
urban areas
Figure 2: MCS in urban and rural areas.
are consistentwith previous studies that showed a role ofmer-
cury in immune activation, enhancing B-cell IgE polyclonal
production. Biochemical changes, including changes in the
serum (liver) alanine aminotransferase (ALT) levels and
aspartate aminotransferase (AST) levels (the latter is more
reliable indicator formercury-induced liver injury), were also
not significantly different from normal range in our cohort
(data not shown). No significant changes in lead blood con-
centrations (possible plumbism) were found in 10 (10 of 41,
24.3 percent) patients, and no interaction between mercury
and lead blood levels was seen in these patients (data not
shown).
3.16. Rural-Urban Differences and the Prevalence of MCS. 22
of 41 (53.6 percent) of MCS patients were located in large
metropolitan urban areas, where exposure to fine-particulate
air pollution has been associated with increased morbidity.
19 of 41 (46.3 percent) were patients who live in rural areas
(Figure 2).There was no a statistical difference in the number
of patients living in urban compared with rural areas. In two
urban Milan (Italy) sites, we measured real-time ambient air
mercury vapor concentrations (outdoor Milan atmospheric
Hg0) and was approximately 50 nanograms per cubic meter,
and it was detected by cold vapor atomic fluorescence spec-
troscopy (CVAFS). Outdoor air levels of mercury in urban
area were considerably lower than those released from dental
amalgam into the oral cavity in a case series of our patients
with mercury amalgam fillings (i.e., 50 nanograms per cubic
meter versus 15–30 micrograms per cubic meter, during
mastication).
3.17. Exposure to Pesticides. Some studies have previously
highlighted a link between pesticides exposures and the
development ofMCS [20, 22, 24, 52–55].Wewere surprised to
see that some of our patients applied in-home and/or outdoor
pesticides at their residence, even after the diagnosis of MCS.
3.18. Exposure to Pets. Of 28 patients interviewed about
lifetime indoor pet exposure, 10 of 28 (35.7 percent) reported
exposure to pets, mainly cats (90 percent).
3.19. Exposure to Solvents and MCS. Thirty-nine percent (16
of 41, 39 percent) of the cohort reported having had adverse
events to organic solvents. In some instances, we witnessed
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episodes of clinical important aversive response to organic
solvents involving respiratory system (bronchial hyperre-
activity and asthma attacks) and central nervous system
(vasovagal response: fainting and/or near-fainting, dizziness,
vertigo, low blood pressure, and tremor) triggered by acute
(short-term) inhalation exposures to organic solvents. Of the
28 patients who could be evaluated, (28 of 41, 68 percent)
chemical odor intolerance (i.e., hyperosmia, cacosmia, and
dysosmia) was self-reported in 24 of 28 (85.7 percent). In
somepatients the perception of chemical odor (i.e., perfumes,
fragrances, hairsprays, cigarette smoke, and diesel fumes)
persists some days after exposure.
3.20. Dietary Supplements and Antioxidant Supplements.
Professionals usually recommended supplements as a sup-
portive therapy to reduce mercury burden. In theory, these
supplements would bind and detoxify mercury that can be
deposited in parenchymal pattern, reestablishing and main-
taining the hepatic glutathione stores (i.e., N-acetylcysteine
(NAC), selenium, and reduced glutathione, GSH). By con-
trast, there is no documented evidence either in animalmodel
or in outcome studies that support therapy with supplements
is able to remove mercury from human tissues [56]. Our
observations raise the possibility that treatment with vita-
mins, minerals, and antioxidants did not ameliorate the
symptoms in most patients with MCS. In particular, we
suggest that important clinical adverse events associated with
oral supplements should be carefully evaluated when these
nonspecific supportive therapies are prescribed to persons
who have a clear history of mercury amalgam exposure, for
example, ascorbic acid and thiol (sulfur derivatives) agents.
Vitamin C (ascorbic acid) was not able to mobilize and
remove mercury from tissues in both human and animal
studies [56, 57]. Rather, some antioxidants worsen the
retention kinetics of mercury in patients exposed to dental
amalgam. 5 of 41 (12.2 percent) patients received secondary
supportive therapy: 3 patients received selenium, 1 patient
received alpha lipoic acid (ALA), and 1 received N-acetyl-
cysteine (NAC). Adverse health effects occurred in 3 of 5 (60
percent). In two (2) of them, supplementation with selenium
has been implicated in an elevation of the levels of serum
antinuclear antibodies (ANAs) and one patient developed
severe major aphthous stomatitis, whereas panic attacks were
associated with the oral administration of alpha lipoic acid
(ALA). 7 of 10 patients who have received intravenous (iv)
administration of reduced glutathione (GSH) by continuous
infusion, 5 of 7 (70 percent) patients had various adverse
events while receiving GSH, including urticaria, asthma
attacks, worsening of MCS symptoms, and cheilitis.
3.21. Chelation Therapy and MCS. Chelating agent-related
toxic effect was reported to us by one patient who underwent
a tentative treatment of mercury-chelation therapy. This
patient, one of 41 (2.4 percent) received calcium EDTA
(ethylenediaminetetraacetic acid—EDTA) by intravenous
(iv) continuous infusion [57]. This approach with chelating
agents for “detoxification” of mercury was suggested by other
physicians, and in our view, it should be used with great cau-
tion. Chelation and mobilizing agents are usually contraindi-
cated in patients with mercury-containing dental amalgam
fillings [58, 59].
3.22. Interactions between Mercury and Other Metals
3.22.1. Mercury and Chromium. In our accumulated clinical
experience, chromium allergy and/or chromium exposure
appear to confer a considerable susceptibility to mercury
exposure. The relation between such biochemical interaction
in humans is currently unclear. In our case series of 41, in 4 of
26 patients the point prevalence of allergy to chromium was
15.4 percent.
3.22.2. Mercury and Titanium. We also observed a poten-
tial interaction between mercury amalgam restorations and
endosseous dental titanium implants among 4 patients in our
group with MCS (9.8 percent, 4 of 41). In these 4 patients, we
have noted important neurological adverse events (i.e., per-
sistent idiopathic facial pain).
3.22.3. Mercury and Gold. Both metallic mercury (Hg0) and
gold may elicit autoimmunity in humans and experimental
animals. Some early studies suggest that after the removal
of mercury dental amalgam serum antinuclear antibodies
(ANAs) frequently reverted to negative [60].
4. Discussion
A surprisingly very high prevalence of allergic sensitization
to metals (92.3 percent) was detected among 26 of 41 patients
with MCS in our cohort. Consistent with our findings, other
studies have reported a high prevalence of allergy among per-
sons with a diagnosis of MCS [61]. In this study, patients with
MCS had significantly higher prevalence of allergy and/or
immune sensitization to metals with respect to the general
population and were more likely to have both fibromyalgia
(FM) and chronic fatigue syndrome (CFS) [62].
Combined skin patch testing and lymphocyte transfor-
mation test (LTT) were sufficiently sensitive and specific to
provide important clinical guidance.
Importantly, mercury-containing dental amalgam filling
was associated with increased odds of elevation of mercury
in biological indicator media (blood, urine, saliva, and scalp
hair). An unexpected finding of our study is the very high
salivary mercury levels (mean 38.1 ± 52.1 micrograms per
liter, threshold limit values <2.7) in MCS patients who
have mercury-containing dental amalgam. It appears that
saliva mercury levels were significantly higher in individuals
affected by MCS, as compared with other cohorts. Mercury
amalgam tattoo—the clinical hallmark of dental amalgam—
was more prevalent among patients with MCS than the
population-based prevalence (17 versus 8 percent) [49]. The
potential toxicity of mercury-containing dental amalgam
has been underestimated for a long time in patients with
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underlyingMCS. Nearly 33 percent of the patients were given
a diagnosis of MCS after dental amalgam removal treatment,
thus, there is a clear evidence that unsafe and inaccurate
removal of mercury amalgam is a major risk factor for MCS.
According to our experience and on the basis of data from the
literature [63],many patients reported symptomatic improve-
ment of MCS after complete removal of mercury-containing
dental amalgam as well as other dental alloy restorations
(especially palladium- and gold-based alloys) [63].
4.1. Mercury Toxicity. Mercury has no known biological role
in normal human metabolism. In all of its chemical forms,
mercury is able to increase the production of reactive oxygen
species (ROS) and the subsequent oxidative stress, potentially
causing DNA damage [64]. Mechanisms of mercury toxicity
also include inactivation of enzymes (mainly sulfhydryl
groups—SH), disruption of membranes, and altered neuro-
transmitters [56]. A well-known toxic endpoint of mercury
is the immune system, in fact, immunotoxic effects on
cytokines production (elevated serum interleukin-2 receptor)
and autoimmune disorders have been described in the liter-
ature [56, 60]. Mercury amalgam is a direct toxicant but it
is also a health hazard because of its conversion (biomethy-
lation), owing to oral bacteria biotransformation from inor-
ganicmercury to organicmercury [65]. Experimentally, three
chemical species of mercury are present in saliva specimens
in individuals carryingmercury-containing amalgamfillings:
metallic mercury (Hg0), inorganic mercury (mainly inor-
ganic divalent mercury Hg2+), and organomercury com-
pounds (as mono methyl mercury—CH
3
Hg+—and ethyl
mercury—CH
3
CH
2
Hg+) [65–67]. Consequently, adverse
events to inorganic and/or organic mercury content in saliva
may involve both immune and non immune mechanisms.
4.2. Caveats about Mercury Biomonitoring. Whole blood and
urine mercury levels are believed to be a reliable marker for
recent exposure to inorganic and elemental mercury (Hg0).
Therefore, monitoring blood and urine is valuable for identi-
fying patients with acute exposure to mercury. With ongoing
exposures, however, tissue levels of mercury in humans
are increased due to accumulation [68], especially in brain
(pituitary gland and cerebral cortex), central nervous system,
thyroid, and kidneys, as established in previous studies from
postmortem examinations [59, 68, 69]. This may elucidate
why monitoring blood concentrations of total mercury is of
questionable clinical relevance as indicator of tissues body
burden ofmercury released fromdental amalgam in humans.
Consistently, preclinical studies have suggested direct evi-
dence that low circulating mercury levels could reflect mer-
cury disposition and redistribution to target organs, at least
in adult sheep model [68]. Hence, concentrations of mercury
in blood and urine may underestimate retention toxicity of
mercury in the tissues and organs. In other words, there is the
possibility that measurements of mercury in blood and urine
do not fully reflect the actual mercury amalgam burden in
humans [59].
4.3. Clinical Toxicology of Mercury. Patients with clinical
signs and symptoms of unrecognized chronic mercury expo-
sure from dental amalgam fillings—which is frequently over-
looked onphysical examination—are likely to have amisdiag-
nosis of postviral syndrome, endocrine disorders, or psychi-
atric dysfunction [4]. Therefore, due to a lack of specificity,
particularly early signs of mercury toxicity, a delay in diag-
nosis of “micromercurialism” (also known as the “asthenic-
vegetative syndrome”) is common, as observed within our
cohort. None of the 41 subjects in our present study received
a diagnosis of celiac disease (or non-celiac gluten sensitivity)
whose condition is associated with increased levels of mer-
cury in both blood and urine [70]. A transient, acute overex-
posure tomercury vapors (Hg0) released frommercury amal-
gam during drilling cannot rule out the likelihood of long-
termhealth risks [48]. Of note, signs and symptoms caused by
chronic exposure to various forms ofmercury generated from
amalgam are characterized by a very long-lasting latency
period of more than 5 or 7 years, as previously investigated
[71]. Excluding patients in whom the initiation ofMCS symp-
toms was related to mercury amalgam removal (11 of 33, 33.3
percent), the median times of exposure to mercury amalgam
restorations were approximately 20–25 years before the onset
of adverse health outcome [72]. With regard to the chronic
fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and
fibromyalgia conditions (FM), our results are similar to those
reported previously, inwhich several small studies have docu-
mented an association between mercury amalgam exposure
and CFS/FM [50, 73–76]. In most reported cases of CFS in
patients in our series, the features of CFS and the “asthenic-
vegetative syndrome” caused by inhalation of mercury vapor
overlap significantly.
4.4. Electromagnetic Hypersensitivity: EHS. The causes of
electromagnetic hypersensitivity are not clear and are prob-
ably multifactorial, however, we speculate that tissues and
organs of the body respond to cellular retention and injury
of mercury with inflammation (proinflammatory microenvi-
ronment). Exposure to electromagnetic field might increase
mercury mobilization of metal ions from tissues, which in
turn increases inflammation and oxidative damage to cellular
level [77–81].
4.5. Mercury in Fish. Additional pathway of exposure to
mercury in humans derived from fish consumption, mainly
as organicmercury (CH
3
Hg+). But althoughwe recognize the
potential benefits of eating fish, we are concerned about the
possible overlapping toxic effects of elemental mercury (Hg0)
emitted from dental amalgams and organic mercury expo-
sure (CH
3
Hg+) from fish intake. Patients who already have
mercury overload from amalgamfillingsmay be the least able
to tolerate additionalmercury burden fromdietary fish intake
and should not be further exposed to organic mercury from
fish consumption during amalgam-treatment replacement
[82].
4.6. Limitations of the Study. There are notable limitations
to our study. We did not perform mercury assessments in
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all the patients and the central limitation is the quantity of
missing data. Further, being a retrospective study and as the
sample size is fairly small (forty-one case subjects), it should
be interpreted with caution.
4.7. Interpretation. Studies have documented the increased
risks of adverse events associated with exposure to chemical
substances among patients with MCS [16, 18–20, 83, 84]. A
substantial proportion of our MCS patients (81.2 percent, 26
of 32) had an elevation in the total mercury levels at the
time of the first study visit, and they correlated significantly
with the total number ofmercury-containing dental amalgam
fillings. As far as we are aware, this is the first observation of
quantitative assessment of the association between increased
elevations of mercury in biological indicator media and risk
of MCS. It is therefore reasonable to assume that exposure to
mercury might contribute to the observed symptoms among
patients affected by MCS [53, 54, 85] and that measurements
of mercury levels may be clinically useful. It is also not
inconceivable that previous exposure to organic solvents (and
VOCs)may determine susceptibility tometals in humans, but
the mechanisms are not clear. Further studies are needed to
document that levels of mercury are increased among indi-
viduals with MCS and are able to trigger the disease process.
5. Conclusions
This study indicates that there is an increased prevalence of
allergy to metals among patients withMCS, whereas a higher
level of mercury in biological matrices is associated with the
presence of mercury-containing dental amalgam fillings.
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